TREM2 stabilizing antibodies, Novartis AG, patent grant
Summary
The USPTO granted Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein. The patent names nine inventors and includes 10 claims, establishing Novartis's exclusive rights to this antibody technology.
What changed
The USPTO issued Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein and methods of using these antibodies. The application was filed on September 23, 2022, and the patent grants Novartis exclusive proprietary rights to this TREM2 stabilizing antibody technology.
For pharmaceutical and biotech companies developing TREM2-targeting therapies, this patent establishes Novartis's intellectual property position in this therapeutic space. Competitors working on similar neurodegeneration or immunology therapies may need to conduct freedom-to-operate analyses or explore licensing arrangements with Novartis.
What to do next
- Monitor for updates
- Review patent claims for freedom-to-operate
- Assess licensing opportunities
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREM2 stabilizing antibodies
Grant US12595305B2 Kind: B2 Apr 07, 2026
Assignee
Novartis AG
Inventors
Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
Abstract
The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
CPC Classifications
C07K 16/2803 C07K 2317/565 C12N 15/70
Filing Date
2022-09-23
Application No.
17934795
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.